Oscar R Fajardo-Ramírez1,2,3, María C Barboza-Cerda4, Rocío Ortiz-López1,5, Augusto Rojas-Martínez1,5, María L Garza-Rodríguez2, Abel Sepúlveda-Flores6, Juan F González-Guerrero6, Sofía Bernal-Silva7, Ricardo M Cerda-Flores8, Itzel E Calleja-Macías9, Socorro Rodríguez-Flores10, Esthela Sandoval-Guzmán10, Teresa Plascencia-Solis10, Patricia Pérez-Reyes10, Jesús Z Villarreal10, Hugo A Barrera-Saldaña2. 1. Tecnologico de Monterrey, Escuela Nacional de Medicina y Ciencias de la Salud, Monterrey, Mexico. 2. Facultad de Medicina, Departamento de Bioquimica y Medicina Molecular, Universidad Autónoma de Nuevo Leon, San Nicolás de los Garza, Mexico. 3. Departamento de Ciencias Basicas, Universidad de Monterrey, San Pedro Garza García, Mexico. 4. Servicio de Anatomía Patológica y Citopatología, Hospital Universitario "José Eleuterio González", Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico. 5. Centro de Investigación y Desarrollo en Ciencias de la Salud, Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico. 6. Centro Universitario contra el Cáncer, Hospital Universitario "Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico. 7. Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico. 8. Facultad de Enfermeria, Universidad Autónoma de Nuevo León, San Nicolás de los Garza, Mexico. 9. Department of Molecular Biology and Biochemistry, University of California at Irvine, Irvine, CA, USA. 10. Secretaría de Salud de Nuevo León, Monterrey, Mexico.
Abstract
OBJECTIVE: To investigate clinical outcomes and 3-year persistence of human papillomavirus (HPV) infections among women in Mexico. METHODS: A prospective study enrolled sexually active women attending primary healthcare clinics in metropolitan Monterrey, Mexico, between June 3 and August 30, 2002. Baseline data were collected and participants underwent HPV screening. Patients with HPV infections were asked to attend a repeat screening appointment after 3 years, when the same screening data were gathered. Descriptive analyses were performed and the prevalence of cervical lesions and viral infections were examined. RESULTS: In total, 1188 patients who underwent initial HPV screening were included. Cervical lesions were detected in 5 (0.4%) patients and 239 (20.1%) patients had HPV infections; 129 (54.0%) of these patients attended 3-year follow-up. Among the 357 HPV serotypes identified, the most prevalent serotypes were HPV-59, HPV-52, HPV-16, and HPV-56, detected 62 (17.4%), 38 (10.6%), 27 (7.6%), and 18 (5.0%) times, respectively. Of the 129 patients attending 3-year follow-up, 104 (80.6%) were clear from HPV infections, 13 (10.1%) patients had persistent HPV infections, and 12 (9.3%) had HPV infections with different HPV types. CONCLUSIONS: The HPV prevalence was 20.1% in the present study; the most prevalent infections were HPV-59, HPV-52, HPV-16, and HPV-56. At 3-year follow-up, 25 (19.4%) patients had HPV infections.
OBJECTIVE: To investigate clinical outcomes and 3-year persistence of human papillomavirus (HPV) infections among women in Mexico. METHODS: A prospective study enrolled sexually active women attending primary healthcare clinics in metropolitan Monterrey, Mexico, between June 3 and August 30, 2002. Baseline data were collected and participants underwent HPV screening. Patients with HPV infections were asked to attend a repeat screening appointment after 3 years, when the same screening data were gathered. Descriptive analyses were performed and the prevalence of cervical lesions and viral infections were examined. RESULTS: In total, 1188 patients who underwent initial HPV screening were included. Cervical lesions were detected in 5 (0.4%) patients and 239 (20.1%) patients had HPV infections; 129 (54.0%) of these patients attended 3-year follow-up. Among the 357 HPV serotypes identified, the most prevalent serotypes were HPV-59, HPV-52, HPV-16, and HPV-56, detected 62 (17.4%), 38 (10.6%), 27 (7.6%), and 18 (5.0%) times, respectively. Of the 129 patients attending 3-year follow-up, 104 (80.6%) were clear from HPV infections, 13 (10.1%) patients had persistent HPV infections, and 12 (9.3%) had HPV infections with different HPV types. CONCLUSIONS: The HPV prevalence was 20.1% in the present study; the most prevalent infections were HPV-59, HPV-52, HPV-16, and HPV-56. At 3-year follow-up, 25 (19.4%) patients had HPV infections.
Authors: C M Luna-Aguirre; L M Reyes-Cortés; A A Torres-Grimaldo; S F Karr-de-León; R M Cerda-Flores; B Melo-Nava; V E Aizpuru-Akel; H A Barrera-Saldaña Journal: Epidemiol Infect Date: 2018-06-27 Impact factor: 4.434
Authors: Andrea Molina-Pineda; María Guadalupe López-Cardona; Laura Patricia Limón-Toledo; Juan Carlos Cantón-Romero; María Guadalupe Martínez-Silva; Holanda Vanesa Ramos-Sánchez; María Guadalupe Flores-Miramontes; Pedro de la Mata-González; Luis F Jave-Suárez; Adriana Aguilar-Lemarroy Journal: BMC Infect Dis Date: 2020-11-25 Impact factor: 3.090
Authors: Mariel A Oyervides-Muñoz; Antonio A Pérez-Maya; Celia N Sánchez-Domínguez; Anais Berlanga-Garza; Mauro Antonio-Macedo; Lezmes D Valdéz-Chapa; Ricardo M Cerda-Flores; Victor Trevino; Hugo A Barrera-Saldaña; María L Garza-Rodríguez Journal: Viruses Date: 2020-03-31 Impact factor: 5.048